Crinetics Pharmaceuticals (CRNX) Liabilities and Shareholders Equity (2017 - 2026)

Crinetics Pharmaceuticals' Liabilities and Shareholders Equity history runs 10 years deep, the most recent figure standing at $1.4 billion for Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity rose 2.94% year-over-year to $1.4 billion in Q1 2026; TTM through Mar 2026 was $5.0 billion, a 7.38% increase from a year earlier, with the FY2025 full-year figure at $1.1 billion, down 21.49% from the prior year.
• Liabilities and Shareholders Equity rose to $1.4 billion in Q1 2026 per CRNX's latest filing, from $1.1 billion in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $1.4 billion in Q4 2024 and bottomed at $293.3 million in Q2 2023.
• The 5-year median for Liabilities and Shareholders Equity is $935.5 million (2024), against an average of $825.7 million.
• Across the five-year window, Liabilities and Shareholders Equity plunged 30.46% in 2023 and soared 219.02% in 2024, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $352.2 million in 2022, then jumped by 80.41% to $635.4 million in 2023, then jumped by 125.79% to $1.4 billion in 2024, then fell by 21.49% to $1.1 billion in 2025, then climbed by 24.42% to $1.4 billion in 2026.
• Per Business Quant, the three latest CRNX Liabilities and Shareholders Equity figures stand at $1.4 billion (Q1 2026), $1.1 billion (Q4 2025), and $1.2 billion (Q3 2025).